Skip to main content

Table 3 Best radiological response per protocol arm

From: TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

Best radiological responsesLetrozole, n = 25Letrozole/bevacizumab, n = 49
n (%)95% CIn (%)95% CI
Complete response (%) (no evidence of residual tumor)1 (4)0.1%, 20.4%5 (10)3.4%, 22.2%
Partial response16 (64)42.5%, 82.0%34 (69)54.6%, 81.7%
Objective response rate17 (68)46.5%, 85.1%39 (79)65.7%, 89.8%
Stable disease7 (28)12.1%, 49.4%10 (21)10.2%, 34.3%
Progressive disease1 (4)0.1%, 20.4%0 (0)0, 7.3%
Mean tumor maximum diameter change− 39%− 26.4, − 52.2− 51%− 43.5, − 58.6
  1. Exact (Clopper-Pearson) confidence interval